As part of a larger effort to attack competition issues in several markets, the antitrust division of the U.S. Department of Justice is planning to file criminal charges against the generic drug industry for alleged price fixing, Assistant Attorney General Makan Delrahim told The Wall Street Journal in an interview.
While the department has been conducting criminal investigations into generic drug companies for years, federal cases have been slow to emerge. So far, two companies and two executives have been charged. Most recently, Rising Pharmaceuticals was charged with fixing prices on a hypertension drug and agreed to pay restitution and civil damages.
State officials have also been pursuing separate civil cases against the generic drug industry.